Label Comprehension Guidance May Improve Switch Outlook

Final guidance for label comprehension studies replaces several draconian draft recommendations with more flexible "common sense" measures, but drug sponsors may need to conduct significantly larger, more expensive studies and meet more extensively with the agency, experts say